Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Salmeterol + fluticasone is a fixed-dose combination inhaled medication used for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It contains two active ingredients: - Fluticasone propionate, an inhaled corticosteroid that reduces inflammation in the airways. - Salmeterol xinafoate, a long-acting beta2-adrenergic agonist (LABA) that relaxes bronchial smooth muscle to improve airflow. This combination is not intended for acute relief of asthma or COPD symptoms but as a controller therapy to reduce exacerbations and maintain lung function. It is administered via oral inhalation using specific devices such as Diskus or HFA inhalers[1][3][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on salmeterol + fluticasone.